Life sciences company Avantor (NYSE:AVTR) fell short of the market’s revenue expectations in Q4 CY2024, with sales falling 2.1% year on year to $1.69 billion. Its non-GAAP profit of $0.27 per share was 4.5% above analysts’ consensus estimates.
Avantor (AVTR) Q4 CY2024 Highlights:
Revenue: $1.69 billion vs analyst estimates of $1.71 billion (2.1% year-on-year decline, 1.6% miss)
Adjusted EPS: $0.27 vs analyst estimates of $0.26 (4.5% beat)
Adjusted EBITDA: $307.7 million vs analyst estimates of $301.8 million (18.2% margin, 1.9% beat)
Operating Margin: 37.8%, up from 10.6% in the same quarter last year
Free Cash Flow Margin: 8.6%, down from 11.7% in the same quarter last year
Organic Revenue rose 1% year on year (-5.9% in the same quarter last year)
Market Capitalization: $14.77 billion
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.